Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARA-002 in BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer
NCT07480356Phase 3Recruiting
- Sponsor
- Protara Therapeutics
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
A Phase 3 trial of TARA-002 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Protara Therapeutics. Started May 2026; status: recruiting.
02
Drugs
TARA-002
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07480356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480356.